Thermo Fisher Scientific Specialty Diagnostics — Restructuring and other costs decreased by 100.0% to $0.00 in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $4.25M to $0.00. This is a positive signal — lower values indicate better performance for this metric.
High costs may indicate short-term pain for long-term efficiency gains, while consistently low costs suggest operational stability.
Expenses incurred to reorganize, streamline, or optimize the operations of the Specialty Diagnostics segment. This inclu...
Commonly reported by large-cap firms undergoing periodic operational transformations.
tmo_segment_specialty_diagnostics_restructuring_and_other_costs| Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.00M | $2.00M | $2.75M | $2.75M | $2.75M | $2.75M | $4.25M | $4.25M | $4.25M | $4.25M | $0.00 |
| QoQ Change | — | +100.0% | +37.5% | +0.0% | +0.0% | +0.0% | +54.5% | +0.0% | +0.0% | +0.0% | -100.0% |
| YoY Change | — | — | +175.0% | +37.5% | — | — | +54.5% | +54.5% | +54.5% | +54.5% | -100.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.